Damora Therapeutics (DMRA) Capital Expenditures (2021 - 2025)
Damora Therapeutics (DMRA) posted Capital Expenditures of -$837000.0 for Q4 2025, down 383.73% on a QoQ basis from $295000.0 in Q3 2025, and up 56.94% year-over-year from -$533309.7 in Q4 2024.
Damora Therapeutics (DMRA) Capital Expenditures (2021 - 2025) Analysis & Trends
Damora Therapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at -$837000.0 for Q4 2025.
- Quarterly Capital Expenditures rose 56.94% year-over-year to -$837000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$166000.0 (up 82.89% YoY) and the FY2025 annual result came in at -$166000.0, up 82.89% from the prior year.
- Capital Expenditures was -$837000.0 for Q4 2025 at Damora Therapeutics, down from $295000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $776000.0 in Q2 2021 and bottomed at -$1.9 million in Q4 2024.
- A 5-year average of -$90200.0 and a median of $83500.0 in 2021 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 1363.73% — and 2024, when it surged 3155.56%.
- Damora Therapeutics' Capital Expenditures stood at $20000.0 in 2021, then soared by 410.0% to $102000.0 in 2022, then tumbled by 1363.73% to -$1.3 million in 2023, then sank by 50.81% to -$1.9 million in 2024, then jumped by 56.94% to -$837000.0 in 2025.
- Business Quant data shows DMRA's Capital Expenditures at -$837000.0 in Q4 2025, $295000.0 in Q3 2025, and $225000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -837,000.00 |
| Dec 31, 2025 | -837,000.00 |
| Sep 30, 2025 | 295,000.00 |
| Sep 30, 2025 | 295,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Mar 31, 2025 | 151,000.00 |
| Mar 31, 2025 | 151,000.00 |
| Dec 31, 2024 | -1.94 Mn |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | 117,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Mar 31, 2024 | 582,000.00 |
| Mar 31, 2024 | 582,000.00 |
| Dec 31, 2023 | -1.29 Mn |
| Dec 31, 2023 | -1.29 Mn |
| Sep 30, 2023 | -62,000.00 |
| Sep 30, 2023 | -62,000.00 |